OSE Immunotherapeutics Share Price
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
16:55:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.986 EUR | -2.74% |
|
-6.39% | -42.02% |
| 09-02 | OSE Immunotherapeutics SA - Special Call | |
| 08-19 | Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine | RE |
| Market Cap | 70.23M 81.62M 66.08M 60.36M 113M 7.71B 113M 781M 303M 3.95B 306M 300M 12.74B | P/E 2026 * |
-2.29x | P/E 2027 * | -2.63x |
|---|---|---|---|---|---|
| Enterprise Value | 111M 129M 104M 95.42M 179M 12.18B 179M 1.23B 479M 6.25B 484M 474M 20.13B | EV / Sales 2026 * |
22.7x | EV / Sales 2027 * | 12.7x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
Börse Stuttgart
| 6OP | Delayed | |
|
CBOE
| OSEp | Real-time | |
|
Tradegate
| 6OP | Real-time | |
|
Boerse Muenchen
| 6OP | Real-time | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time |
Last Transcript : OSE Immunotherapeutics
| 1 day | -2.74% | ||
| 1 week | -6.39% | ||
| Current month | -7.15% | ||
| 1 month | -7.04% | ||
| 3 months | -19.30% | ||
| 6 months | -29.28% | ||
| Current year | -42.02% |
| 1 week | 2.92 |  | 3.32 |
| 1 month | 2.92 | | 3.54 |
| Current year | 2.87 | | 5.9 |
| 1 year | 2.87 | | 7.7 |
| 3 years | 2.87 | | 11.58 |
| 5 years | 2.7 | | 13.68 |
| 10 years | 2.7 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 01/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 19/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 19/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 30/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 13/06/2017 |
| Director/Board Member | - | 21/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/11/24 | Sell | Director | 30,000 | 0.1375% | ||
| 12/11/24 | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 21/06/24 | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.74% | -6.39% | -50.44% | -19.73% | 81.62M | |
| -2.54% | -2.84% | -1.90% | +14.52% | 48.93B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.01B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.07B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 40.73B | |
| +0.53% | -1.36% | +16.04% | +48.23% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.5B | |
| -1.01% | +0.50% | +15.83% | +27.98% | 14.67B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 13.77B | |
| Average | -1.10% | -0.16% | +64.10% | +90.54% | 27.51B | |
| Weighted average by Cap. | -1.03% | +0.11% | +94.81% | +122.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.69M 4.61M 4.21M 7.88M 538M 7.9M 54.48M 21.14M 276M 21.38M 20.92M 889M | 10.53M 12.24M 9.91M 9.05M 16.93M 1.16B 16.98M 117M 45.43M 593M 45.95M 44.95M 1.91B |
| Net income | -30.59M -35.54M -28.78M -26.29M -49.18M -3.36B -49.31M -340M -132M -1.72B -133M -131M -5.55B | -21.47M -24.95M -20.2M -18.45M -34.52M -2.36B -34.61M -239M -92.61M -1.21B -93.68M -91.64M -3.89B |
| Net Debt | 40.79M 47.4M 38.38M 35.06M 65.58M 4.48B 65.76M 454M 176M 2.3B 178M 174M 7.4B | 63.08M 73.31M 59.35M 54.22M 101M 6.92B 102M 701M 272M 3.55B 275M 269M 11.44B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | €2.986 | -2.74% | 244,384 |
| 03/09/26 | €3.070 | -4.42% | 196,258 |
| 02/09/26 | €3.212 | +0.50% | 117,228 |
| 01/09/26 | €3.196 | -0.62% | 69,800 |
| 31/08/26 | €3.216 | +0.82% | 57,350 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
